GSK
GSK announces AllTrials support
February 6, 2013Research and Development, Sales and Marketing ABPI, Bad pharma, GSK, Goldacre
GlaxoSmithKline has this morning found itself in the unusual position of being showered with praise by one of its fiercest …
GSK slams Guardian article
January 31, 2013Sales and Marketing Avandia, FDA, GSK, Guardian
GlaxoSmithKline has slammed an article about its controversial diabetes treatment Avandia in The Guardian newspaper, saying that some of it …
GSK appoints Hans Wijers to its Board as a non-executive director
January 28, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, hans Wijers
GSK has confirmed the appointment of Hans Wijers to its Board as a non-executive director with effect from April. The …
EU submission for GSK and Theravance COPD drug
January 11, 2013Sales and Marketing COPD, GSK, Theravance, UMEC/VI
GlaxoSmithKline and Theravance have submitted their chronic obstructive pulmonary disease (COPD) drug UMEC/VI to European regulators. The application follows the …
GSK’s Promacta extends US licence
November 22, 2012Sales and Marketing FDA, GSK, Promacta, Revolade
GlaxoSmithKline’s Promacta has received a new indication from the FDA which means it can be used for patients with thrombocytopenia …
Pfizer and GSK end agreements
November 12, 2012Research and Development, Sales and Marketing Auxilium, GSK, Pfizer, Xenoport
Pfizer and GlaxoSmithKline are both handing back the rights to two drugs in April 2013 as part of the termination …
GSK guilty of off-label promotion
November 9, 2012Medical Communications, Sales and Marketing GSK, PMCPA, Revolade
GlaxoSmithKline has been found to have breached three clauses in the ABPI Code of Practice following a complaint from a …
Janssen and GSK in hep C tie-ups
November 8, 2012Research and Development, Sales and Marketing GSK, Janssen, Vertex, hep C
Janssen and GlaxoSmithKline are to conduct separate Phase II studies with Vertex Pharmaceuticals to test an investigational all-oral regimen to …
GSK hit by European austerity again
November 1, 2012Sales and Marketing Europe, GSK, Q3, austerity
GlaxoSmithKline suffered in the third quarter as sales fell 5% due to generic competition and austerity measures in Europe.Exceptional sales …
Reprieve for GSK’s Sligo plant
October 16, 2012Manufacturing and Production GSK, Ireland, Sligo, cuts
GlaxoSmithKline has reversed its earlier plan to close a manufacturing plant in Sligo, Ireland, and says it now intends to …
GSK signs TB vaccine agreement
October 11, 2012Research and Development, Sales and Marketing Aeras, GSK, TB
GlaxoSmithKline Vaccines has signed a deal with US not-for-profit biotech Aeras to develop a new vaccine which will treat tuberculosis …
Vernon named Digital Pioneer at PM Society awards
October 5, 2012Medical Communications Creative Lynx, GSK, PM Society Digital Awards, digital
A range of innovative digital programmes created by UK pharma companies and agencies were recognised at last night’s PM Society …
Is it really safety first?
October 2, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Les Rose, Roche
The idea of ensuring that drugs are adequately safe is not very old. Legislation that covers drug safety to the …
Survival boost for Votrient in mRCC
October 2, 2012Research and Development, Sales and Marketing GSK, Nexavar, Pfizer, Sutent, Votrient
GlaxoSmithKline’s renal cell carcinoma drug Votrient has proved itself non-inferior to a bitter rival, Pfizer’s Sutent, in terms of progression-free …
GlaxoSmithKline announces Board changes
September 27, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Witty
GlaxoSmithKline has announced several changes to its Board and Committee structure. The GSK Board of directors with effect from 1 …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
